Eugenio Gaudio

7.0k total citations · 1 hit paper
92 papers, 2.8k citations indexed

About

Eugenio Gaudio is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Eugenio Gaudio has authored 92 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 28 papers in Pathology and Forensic Medicine and 23 papers in Oncology. Recurrent topics in Eugenio Gaudio's work include Lymphoma Diagnosis and Treatment (28 papers), Protein Degradation and Inhibitors (24 papers) and Chronic Lymphocytic Leukemia Research (22 papers). Eugenio Gaudio is often cited by papers focused on Lymphoma Diagnosis and Treatment (28 papers), Protein Degradation and Inhibitors (24 papers) and Chronic Lymphocytic Leukemia Research (22 papers). Eugenio Gaudio collaborates with scholars based in Switzerland, Italy and United States. Eugenio Gaudio's co-authors include Carlo M. Croce, Nicola Zanesi, Hansjüerg Alder, Francesca Lovat, Michael A. Caligiuri, Alessio Paone, Charlene Mao, Paolo Fadda, Muller Fabbri and Dorothee Wernicke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eugenio Gaudio

87 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response

2012 1.3k citations Muller Fabbri, Alessio Paone et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Eugenio Gaudio

Since Specialization

Citations

This map shows the geographic impact of Eugenio Gaudio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugenio Gaudio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugenio Gaudio more than expected).

Fields of papers citing papers by Eugenio Gaudio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugenio Gaudio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugenio Gaudio. The network helps show where Eugenio Gaudio may publish in the future.

Co-authorship network of co-authors of Eugenio Gaudio

This figure shows the co-authorship network connecting the top 25 collaborators of Eugenio Gaudio. A scholar is included among the top collaborators of Eugenio Gaudio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugenio Gaudio. Eugenio Gaudio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive analysis of ¹⁷⁷ Lu ‐lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes 2025 ·British Journal of Haematology ·(unknown), (unknown), (unknown), (unknown), Alberto J. Arribas, Eugenio Gaudio, Roman Generalov, (unknown), Jostein Dahle, Francesco Bertoni	0
2	Targeting CD25 + lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents 2024 ·British Journal of Haematology ·Filippo Spriano, Chiara Tarantelli, (unknown), Eugenio Gaudio, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Patrick H. van Berkel, Giorgio Inghirami, Francesca Zammarchi, Francesco Bertoni	2
3	The ATR inhibitor elimusertib exhibits anti‐lymphoma activity and synergizes with the PI3K inhibitor copanlisib 2023 ·British Journal of Haematology ·Giulio Sartori, Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Luciano Cascione, (unknown), Marilia Barreca, Alberto J. Arribas, (unknown), Gaetanina Golino, (unknown), Stefano Pileri, Giovanna Damia, Emanuele Zucca, Anastasios Stathis, Oliver Politz, Antje M. Wengner, Francesco Bertoni	7
4	Identification of pyrrolo[3′,4’:3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas 2023 ·European Journal of Medicinal Chemistry ·Marilia Barreca, Virginia Spanò, Roberta Rocca, (unknown), (unknown), Maria Valeria Raimondi, Eugenio Gaudio, Roberta Bortolozzi, (unknown), Ruoli Bai, Alessandra Montalbano, Stefano Alcaro, Ernest Hamel, Francesco Bertoni, Giampietro Viola, Paola Barraja	26
5	RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo 2022 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Marianna Nalli, Ruoli Bai, (unknown), (unknown), Eugenio Gaudio, Daniela Trisciuoglio, Filippo Spriano, Patrizia Lavia, Cinzia Fionda, Domiziana Masci, Andrea Urbani, Chiara Bigogno, Giulio Dondio, Ernest Hamel, Francesco Bertoni, Romano Silvestri, Giuseppe La Regina	7
6	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors 2021 ·Blood Advances ·Afua A. Mensah, Filippo Spriano, Giulio Sartori, (unknown), Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, (unknown), Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni	12
7	Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 2020 ·Journal of Medicinal Chemistry ·Virginia Spanò, Roberta Rocca, Marilia Barreca, (unknown), Alessandra Montalbano, Anna Carbone, Maria Valeria Raimondi, Eugenio Gaudio, Roberta Bortolozzi, Ruoli Bai, Pierfrancesco Tassone, Stefano Alcaro, Ernest Hamel, Giampietro Viola, Francesco Bertoni, Paola Barraja	50
8	Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors 2020 ·RSC Medicinal Chemistry ·(unknown), Claudia Jessen‐Trefzer, Dimitrios Spiliotopoulos, Eugenio Gaudio, Chiara Tarantelli, Jing Dong, Hongtao Zhao, (unknown), Stefan Zahler, Elena Bernasconi, Giulio Sartori, Luciano Cascione, Francesco Bertoni, P. Sledz, Amedeo Caflisch, Cristina Nevado	6
9	Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors 2020 ·Molecules ·Annalisa Maruca, (unknown), Roberta Rocca, Antonio Lupia, Giosuè Costa, Raffaella Catalano, Federica Moraca, Eugenio Gaudio, Francesco Ortuso, Anna Artese, Francesco Trapasso, Stefano Alcaro	12
10	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas 2019 ·Molecular Cancer Therapeutics ·(unknown), Monica Lupi, Rosaria Chilà, (unknown), Chiara Tarantelli, Filippo Spriano, Eugenio Gaudio, Francesco Bertoni, Giovanna Damia, Laura Carrassa	29
11	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models 2019 ·Haematologica ·Stuart W. Hicks, Chiara Tarantelli, (unknown), Eugenio Gaudio, Min Li, Alberto J. Arribas, Filippo Spriano, Roberta Bordone, Luciano Cascione, Katharine C. Lai, Qifeng Qiu, Monica Taborelli, Davide Rossi, Georg Stüssi, Emanuele Zucca, Anastasios Stathis, Callum M. Sloss, Francesco Bertoni	18
12	Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach 2018 ·PLoS ONE ·(unknown), Luca Aresu, Serena Ferraresso, (unknown), Eugenio Gaudio, Francesco Bertoni, Mauro Dacasto, Mery Giantin	4
13	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance 2018 ·ESMO Open ·Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, (unknown), Alberto J. Arribas, Filippo Spriano, Andrea Rinaldi, Afua A. Mensah, Ivo Kwee, Maurilio Ponzoni, Emanuele Zucca, Laura Carrassa, María E. Riveiro, Keyvan Rezaï, Anastasios Stathis, Esteban Cvitkovic, Francesco Bertoni	21
14	Abstract 154: The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib 2017 ·Cancer Research ·Eugenio Gaudio, Ivo Kwee, Filippo Spriano, Chiara Tarantelli, Andrea Rinaldi, Thibaud Jourdan, (unknown), (unknown), (unknown), Davide Rossi, Ningshu Liu, Martin Lange, Oliver Politz, Emanuele Zucca, Francesco Bertoni	3
15	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs 2015 ·Clinical Cancer Research ·Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni, Afua A. Mensah, Anastasios Stathis, Georg Stüssi, María E. Riveiro, Patrice Herait, Giorgio Inghirami, Esteban Cvitkovic, Emanuele Zucca, Francesco Bertoni	214
16	Fhit Delocalizes Annexin A4 from Plasma Membrane to Cytosol and Sensitizes Lung Cancer Cells to Paclitaxel 2013 ·PLoS ONE ·Eugenio Gaudio, Francesco Paduano, Riccardo Spizzo, Apollinaire Ngankeu, Nicola Zanesi, Marco Gaspari, Francesco Ortuso, Francesca Lovat, Jonathan Rock, (unknown), Mohamed Kaou, Giovanni Cuda, Rami I. Aqeilan, Stefano Alcaro, Carlo M. Croce, Francesco Trapasso	17
17	MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response breakdown → 2012 ·Proceedings of the National Academy of Sciences ·Muller Fabbri, Alessio Paone, Federica Calore, Roberta Galli, Eugenio Gaudio, Ramasamy Santhanam, Francesca Lovat, Paolo Fadda, Charlene Mao, Gerard J. Nuovo, Nicola Zanesi, Melissa Crawford, Gülçin Özer, Dorothee Wernicke, Hansjüerg Alder, Michael A. Caligiuri, Patrick Nana‐Sinkam, Danilo Perrotti, Carlo M. Croce	1284
18	Frequent Attenuation of the WWOX Tumor Suppressor in Osteosarcoma Is Associated with Increased Tumorigenicity and Aberrant RUNX2 Expression 2010 ·Cancer Research ·Kyle C. Kurek, Sara Del Mare, Zaidoun Salah, Suhaib K. Abdeen, (unknown), Suk‐Hee Lee, Eugenio Gaudio, Nicola Zanesi, Kevin B. Jones, Barry R. DeYoung, Gail Amir, Mark C. Gebhardt, Matthew L. Warman, Gary S. Stein, Janet L. Stein, Jane B. Lian, Rami I. Aqeilan	90
19	Association of Wwox with ErbB4 in Breast Cancer 2007 ·Cancer Research ·Rami I. Aqeilan, Valentina Donati, Eugenio Gaudio, Milena S. Nicoloso, Maria Sundvall, Anna Korhonen, Johan Lundin, Jorma Isola, Marius Sudol, Heikki Joensuu, Carlo M. Croce, Klaus Elenius	95
20	Genetic Ablation of Ptprj , a Mouse Cancer Susceptibility Gene, Results in Normal Growth and Development and Does Not Predispose to Spontaneous Tumorigenesis 2006 ·DNA and Cell Biology ·Francesco Trapasso, Alessandra Drusco, Stefan Costinean, Hansjüerg Alder, Rami I. Aqeilan, Rodolfo Iuliano, Eugenio Gaudio, Cinzia Raso, Nicola Zanesi, Carlo M. Croce, Alfredo Fusco	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact